ASAleksandra Straszewska

Aleksandra Straszewska

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Aleksandra Straszewska has a total of 17 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    EFFECTS OF SEMAGLUTIDE AND TIRZEPATIDE ON SKELETAL MUSCLE MASS AND SARCOPENIA RISK IN ADULTS WITH OBESITY OR OVERWEIGHT: A NARRATIVE REVIEW

    by Szymon Mokrzecki, Anna Mamach, Ewa Bełc, Karolina Brzezińska, Katarzyna Aleksandrowicz, Zofia Grodzka, Mateusz Meszka, Matylda Król, Aleksandra Straszewska, Aleksandra Woźniak, et al.

    Background: GLP-1 receptor agonists (GLP-1 RAs) and dual GLP-1/GIP agonists are highly effective therapies for obesity management. However, associated reductions in lean body mass have raised concerns regarding sarcopenia risk. This review evaluated whether these changes translate into clinically relevant sarcopenia or sarcopenic obesity. Methods: A narrative review of the PubMed, Cochrane Library and Google Scholar databases was conducted up to May 2026, to evaluate GLP-1 receptor agonist effects on muscle mass, body composition, and sarcopenia-related outcomes. Results: GLP-1 RAs produced substantial weight loss, with lean mass accounting for approximately 20–33% of total weight reduction, a proportion comparable to that reported with lifestyle and surgical interventions. Most studies reported preserved or improved muscle function despite reductions in lean mass. MRI studies demonstrated reduced intramuscular fat with only modest decreases in muscle volume. However, one retrospective study in older adults with type 2 diabetes reported concurrent declines in muscle mass and function, suggesting increased vulnerability in high-risk populations. Conclusions: Current evidence does not support a uniformly increased risk of sarcopenia or sarcopenic obesity during GLP-1 RA therapy. Lean mass loss appears largely proportional to overall weight reduction and is generally not accompanied by clinically meaningful declines in muscle function. Older adults and individuals with low baseline muscle reserve may require closer monitoring.

  • Open Access

    THE ROLE OF GUT MICROBIOTA IN THE PATHOGENESIS OF HYPERTENSION - NEW PATHOPHYSIOLOGICAL AND THERAPEUTIC PERSPECTIVES

    by Ewa Bełc, Rafał Borecki, Julia Kierner, Anna Mamach, Katarzyna Aleksandrowicz, Zofia Grodzka, Mateusz Meszka, Matylda Król, Aleksandra Straszewska, Aleksandra Woźniak, et al.

    Background: Hypertension (HT) is a major cardiovascular risk factor, yet traditional models often fail to explain resistant cases. Recent research shifts the focus to the gastrointestinal tract, positioning gut microbiota as a critical modulator of vascular, renal, and neurological functions. Objective: This study analyzes the role of gut dysbiosis in HT pathogenesis, focusing on gut-vascular and gut-brain axes. It synthesizes evidence on how bacterial metabolites, epigenetic mechanisms, and chronic inflammation affect blood pressure homeostasis, evaluating diet and probiotics as supportive therapies. Methods: A review of the current literature in PubMed, Scopus, Google Scholar and ESH/ESC guidelines was conducted, analyzing metagenomic data, animal model studies, and clinical trials regarding the impact of molecular mechanism of metabolic signaling, epigenetic and immunological processes influencing vascular and renal blood pressure regulation. Results: HT patients exhibit a distinct microbiota phenotype, characterized by an increased Firmicutes/Bacteroides ratio and reduced butyrate-producing bacteria. Key metabolic regulators include protective short-chain fatty acids and prohypertensive trimethylamine N-oxide. It has been demonstrated that leaky gut syndrome leads to the translocation of lipopolysaccharide, which induces systemic neuroinflammation. Furthermore, bacterial metabolites act as epigenetic regulators in the kidneys by modulating the activity of histone deacetylases. Conclusion: Gut dysbiosis is an active pathophysiological component of HT. The gut-vascular axis integrates pressure control through immunological hormonal, and neuronal mechanisms. Incorporating targeted diets, probiotics, and psychobiotics into standard protocols offers promising new perspective for HT management.

  • Open Access

    THE PAST, PRESENT, AND FUTURE OF LEADLESS PACEMAKERS: A NARRATIVE REVIEW OF TECHNOLOGICAL EVOLUTION AND CLINICAL EVIDENCE

    by Patrycja Sobantka, Aleksandra Woźniak, Aleksandra Straszewska, Szymon Mokrzecki, Matylda Król, Anna Mamach, Katarzyna Aleksandrowicz, Zofia Grodzka, Mateusz Meszka, Ewa Bełc, et al.

    Background: Conventional transvenous pacemakers (TVPs) have been the gold standard for bradyarrhythmia management for over six decades. However, transvenous leads and the subcutaneous pocket remain the primary sources of acute and chronic morbidity. Recent large-scale meta-analyses confirm that leadless pacemakers (LPMs) systematically eliminate pocket infections and significantly reduce lead-induced valvular complications. Aim: The primary objective of this review is to evaluate the clinical safety, efficacy, and technological progression of leadless pacing systems - from first-generation devices (e.g., Nanostim, Micra VR) to contemporary multi-component modular networks, resynchronization therapies, and novel physiologic sensors. Methods: A comprehensive literature search was performed across major medical databases (PubMed, EMBASE, Cochrane Library) for studies published up to May 2026, focusing on randomized controlled trials, large prospective registries, and clinical updates. Results: First-generation single-chamber ventricular LPMs demonstrated an excellent long-term safety profile in global registries, outperforming historical transvenous cohorts. The contemporary era is characterized by major structural breakthroughs: advanced accelerometer algorithms for mechanical atrial tracking (Micra AV) and dual-chamber leadless pacing systems (AVEIR DR) utilizing intrabody conductive communication for implant-to-implant (i2i) synchronization. Advanced features now include temperature-based rate response and median battery longevity exceeding 15 years. Conclusions: Leadless pacemakers have evolved from a niche solution into a primary therapeutic standard. The future of this field relies on multi-component modular networks (pairing LPMs with subcutaneous ICDs), entirely leadless cardiac resynchronization therapy (CRT) utilizing ultrasound acoustics, and the pursuit of energy-harvesting technologies.

  • Open Access

    ACE INHIBITORS, ANGIOTENSIN RECEPTOR BLOCKERS, AND ANGIOTENSIN RECEPTOR-NEPRILYSIN INHIBITORS IN CONTEMPORARY CARDIOVASCULAR AND RENAL CARE: A NARRATIVE REVIEW

    by Mateusz Meszka, Aleksandra Woźniak, Aleksandra Straszewska, Patrycja Sobantka, Szymon Mokrzycki, Matylda Król, Anna Mamach, Katarzyna Aleksandrowicz, Zofia Grodzka, Ewa Bełc, et al.

    This narrative review critically compares angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), and angiotensin receptor-neprilysin inhibitors (ARNIs) in contemporary cardiovascular and renal care, with particular emphasis on guideline-directed use, safety monitoring, adherence, and treatment implementation. A structured narrative search of PubMed/MEDLINE, Scopus, Web of Science, and the Cochrane Library was completed on 28 June 2026. Randomized trials, systematic reviews, large observational studies, target-trial emulations, and international guideline documents were prioritized. ACEIs and ARBs provide broadly comparable blood pressure reduction and nephroprotection in many populations, whereas ARBs are usually better tolerated, mainly because cough and bradykinin-mediated angioedema are less frequent. ACEIs remain particularly well established after myocardial infarction. ARNIs have the most clearly confirmed advantage in eligible symptomatic patients with HFrEF, but their benefit should not be automatically extrapolated to uncomplicated hypertension, CKD without heart failure, or post-myocardial infarction patients without a heart failure phenotype. Optimal selection requires integration of evidence, laboratory monitoring, availability, costs, and patient preferences.

  • Open Access

    THE IMPACT OF INTERMITTENT FASTING ON WEIGHT REDUCTION AND METABOLIC PARAMETERS — CURRENT STATE OF KNOWLEDGE

    by Aleksandra Straszewska, Aleksandra Woźniak, Patrycja Sobantka, Szymon Mokrzecki, Matylda Król, Katarzyna Aleksandrowicz, Zofia Grodzka, Mateusz Meszka, Ewa Bełc, Karolina Brzezińska, et al.

    Background: Intermittent fasting (IF) has emerged as a widely investigated dietary strategy for the management of obesity and metabolic disorders. Increasing evidence suggests that periodic energy restriction may improve body weight and metabolic parameters associated with cardiovascular disease and type 2 diabetes. Aim: This review aimed to summarize the current evidence regarding the effects of intermittent fasting on body weight reduction, glucose–insulin metabolism, lipid profile, blood pressure, and inflammatory markers. Methods: A narrative review of the literature indexed in PubMed was conducted, focusing primarily on publications from 2020–2025, including randomized controlled trials, systematic reviews, umbrella reviews, and meta-analyses evaluating intermittent fasting in adults with overweight, obesity, metabolic syndrome, or type 2 diabetes. Results: Current evidence indicates that IF may promote moderate weight reduction, decrease visceral adiposity, improve insulin sensitivity, reduce fasting glucose and triglyceride concentrations, and modestly lower blood pressure. Early time-restricted eating appears particularly beneficial due to its alignment with circadian rhythms. However, most studies demonstrate that IF does not significantly outperform conventional caloric restriction when total energy deficit is comparable. Conclusions: Intermittent fasting represents a promising nutritional strategy for improving metabolic health, particularly in individuals with obesity and metabolic syndrome. Nevertheless, long-term adherence, dietary quality, and sustained energy deficit remain the primary determinants of clinical effectiveness. Further long-term randomized controlled trials are required to establish the optimal IF protocols and their long-term safety.

  • Open Access

    Resistance Training as a Candidate Intervention for Aromatase Inhibitor Adherence in Postmenopausal Breast Cancer Survivors: A Narrative Review of Musculoskeletal Outcomes and Adherence Pathway

    by Katarzyna Aleksandrowicz, Aleksandra Woźniak, Matylda Król, Mateusz Meszka, Anna Mamach, Aleksandra Straszewska, Patrycja Sobantka, Oliwia Grygorczuk, Zofia Grodzka, Szymon Mokrzecki, et al.

    The use of adjuvant aromatase inhibitor (AI) therapy decreases recurrence in postmenopausal hormone receptor-positive breast cancer. Survival benefit depends on patients’ compliance to the prescribed course. Up to 85.9% of women report AI-induced musculoskeletal symptoms (AIMSS). In the CANTO cohort AIMSS independently predicted noncompliance (aOR 2.35, 95% CI 1.51–3.64). This narrative review analysed evidence on resistance training (RT) in postmenopausal AI-treated survivors putting an emphasis on the patients’ compliance to proposed treatment.Two cohorts meeting strict inclusion criteria - the HOPE trial and the de Paulo group - together with two boundary cohorts, converge directionally. RT alleviate AIMSS severity, improves body composition, improves quality of life, and is safe to apply to everyday life. In HOPE resistance training combined with aerobic training reduced the worst experienced pain by a 1.8 point (95% CI 0.9–2.6; p<0.001), exceeding the minimal difference which is important clinically. Cochrane GRADE rates the overall evidence as very low. Proposed mechanisms remain biologically plausible but untested in AI-treated survivors.No completed trial has used AI compliance as a primary outcome. The REJOIN trial is yet to be pending. We propose a hypothesis-generating operational prescription - three sessions per week with progressive loading at 55-75% one-repetition maximum, impact components, supervised delivery, minimum nine months - as a target for confirmatory trials with adherence as the primary endpoint.

  • Open Access

    BEYOND GLYCEMIC CONTROL AND WEIGHT REDUCTION: PLEIOTROPIC EFFECTS OF GLP-1 RECEPTOR AGONISTS ON HUMAN PHYSIOLOGY - A NARRATIVE REVIEW

    by Matylda Król, Aleksandra Woźniak, Aleksandra Straszewska, Patrycja Sobantka, Szymon Mokrzecki, Anna Mamach, Katarzyna Aleksandrowicz, Zofia Grodzka, Mateusz Meszka, Ewa Bełc, et al.

    Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have emerged as one of the most important therapeutic advances in the management of type 2 diabetes mellitus and obesity. Originally developed to enhance glucose-dependent insulin secretion and improve glycemic control, these agents have demonstrated a broad spectrum of effects extending beyond traditional metabolic indications. The widespread expression of GLP-1 receptors throughout multiple organ systems provides a biological basis for their pleiotropic actions, which include modulation of inflammatory, vascular, metabolic, and neurohormonal pathways. This narrative review summarizes current evidence regarding the systemic effects of GLP-1RAs beyond diabetes and obesity. Recent landmark clinical trials have demonstrated significant reductions in major adverse cardiovascular events, improvements in heart failure-related outcomes, and slower progression of chronic kidney disease. Emerging evidence also supports beneficial effects in metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH), with improvements observed in hepatic steatosis, inflammation, and fibrosis. In addition, growing interest has focused on the neuroprotective properties of GLP-1RAs, including their potential role in neurodegenerative disorders such as Parkinson’s and Alzheimer’s disease. Modulation of central reward pathways has further raised the possibility of their application in addiction medicine. Additional findings suggest favorable effects in obesity-associated obstructive sleep apnea and reproductive disorders, particularly polycystic ovary syndrome. Observational studies have also explored potential associations with reduced cancer risk and healthy aging, although evidence in these areas remains preliminary. Despite their favorable safety profile and expanding clinical utility, several emerging indications require further validation through large randomized controlled trials. Overall, current evidence supports the view that GLP-1 receptor agonists should be regarded as multisystem therapeutic agents with clinically meaningful effects extending far beyond glycemic control and weight reduction, highlighting their potential to reshape the management of numerous chronic diseases.

  • Open Access

    PSYCHOSOMATIC SYMPTOMS IN ADULTS: PSYCHOLOGICAL AND SOCIAL DETERMINANTS

    by Zofia Grodzka, Jakub Tomasz Latos, Katarzyna Anna Kowalska, Karolina Brzezińska, Ewa Bełc, Mateusz Meszka, Katarzyna Aleksandrowicz, Anna Mamach, Matylda Król, Szymon Mokrzecki, et al.

    Psychosomatic symptoms constitute a significant health concern in contemporary society and are increasingly examined in the context of mental health and social functioning. The aim of this study was to present the psychological and social determinants of psychosomatic symptoms in adults based on current scientific literature. The article discusses the relationships between chronic stress, anxiety disorders, depression, and emotional difficulties and the occurrence of somatic symptoms without a clear organic basis. Particular attention was paid to the role of social factors, including occupational pressure, financial difficulties, social isolation, interpersonal conflicts, and the impact of modern lifestyles on the development of psychosomatic complaints. The analysis of available studies indicates that psychosomatic symptoms may include headaches, gastrointestinal complaints, palpitations, muscle tension, chronic fatigue, and sleep disturbances. Numerous studies have emphasized a strong association between the severity of psychosomatic symptoms and levels of anxiety, stress, and reduced psychological well-being. Mechanisms related to emotion regulation and individual psychological resilience were also found to play an important role. The findings of the literature review highlight the need for a holistic approach to the diagnosis and treatment of psychosomatic symptoms that considers both psychological and social aspects. The importance of mental health promotion, stress reduction strategies, and interventions aimed at improving quality of life among adults was also emphasized.

  • Open Access

    LONELINESS AS A RISK FACTOR FOR CARDIOVASCULAR DISEASE: A NARRATIVE REVIEW

    by Aleksandra Woźniak, Aleksandra Straszewska, Patrycja Sobantka, Szymon Mokrzecki, Matylda Król, Anna Mamach, Katarzyna Aleksandrowicz, Zofia Grodzka, Mateusz Meszka, Ewa Bełc, et al.

    Cardiovascular diseases (CVDs) remain the leading cause of death worldwide, and growing evidence identifies loneliness as an independent psychosocial risk factor for cardiovascular health. This narrative review summarizes current evidence on the biological and behavioral mechanisms linking loneliness with CVD, based on peer-reviewed studies published between 2021 and 2026 retrieved from PubMed, Google Scholar, and Scopus. The literature indicates that loneliness acts as a chronic stressor, promoting activation of the hypothalamic-pituitary-adrenal axis and sympathetic nervous system, which contributes to systemic inflammation, impaired heart rate variability, and increased allostatic load. In addition, it encourages unhealthy behaviors such as smoking, poor diet, physical inactivity, and social withdrawal, further increasing cardiovascular risk. Overall, the evidence suggests that loneliness contributes to both the development and progression of CVD through interconnected biological and behavioral pathways. As a modifiable risk factor, loneliness should be identified early in clinical practice, and addressed through interventions such as social prescribing, cognitive behavioral approaches, and community-based programs.